Serum lysozyme levels in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Biochemistry

Background:

• Crohn's disease (CD) and chronic ulcerative colitis (CUC) are distinct inflammatory bowel diseases.
• Differentiating between CD and CUC is crucial for effective treatment strategies.
• Serum lysozyme levels have been proposed as a potential biomarker for distinguishing these conditions.

Purpose of the Study:

• To investigate whether serum lysozyme levels can differentiate between patients with Crohn's disease and chronic ulcerative colitis.
• To compare serum lysozyme concentrations using multiple assay methods.

Main Methods:

• Serum lysozyme levels were measured in 19 CD and 23 CUC patients.
• Three distinct methods were employed: turbidimetric clearance assay, Osserman and Lawlor lysoplate assay, and a commercial lysoplate kit.
• Patient groups were analyzed based on disease diagnosis and severity (severe, moderate, inactive).

Main Results:

• No statistically significant differences in serum lysozyme levels were observed between CD and CUC patients across all three measurement methods.
• Serum lysozyme levels did not correlate significantly with disease severity (severe, moderate, inactive) in either CD or CUC.
• Serial monitoring of patients did not consistently show correlation between lysozyme levels and clinical course changes.

Conclusions:

• Serum lysozyme levels, as measured by the methods used, are not a reliable indicator for differentiating Crohn's disease from chronic ulcerative colitis.
• The findings contradict previous reports suggesting lysozyme as a distinguishing biomarker.
• Further research may be needed to explore other potential biomarkers for differentiating IBD subtypes.